WallStSmart

McCormick & Company Incorporated (MKC)vsPrenetics Global Ltd (PRE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

McCormick & Company Incorporated generates 6051% more annual revenue ($7.39B vs $120.07M). MKC leads profitability with a 21.9% profit margin vs -42.0%. MKC earns a higher WallStSmart Score of 69/100 (B-).

MKC

Strong Buy

69

out of 100

Grade: B-

Growth: 4.7Profit: 7.5Value: 7.3Quality: 5.0
Piotroski: 4/9Altman Z: 1.58

PRE

Avoid

32

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 7.0
Piotroski: 5/9Altman Z: -0.01
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MKCUndervalued (+27.2%)

Margin of Safety

+27.2%

Fair Value

$96.91

Current Price

$50.90

$46.01 discount

UndervaluedFair: $96.91Overvalued

Intrinsic value data unavailable for PRE.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MKC5 strengths · Avg: 8.8/10
P/E RatioValuation
8.6x10/10

Attractively priced relative to earnings

Return on EquityProfitability
23.3%9/10

Every $100 of equity generates 23 in profit

Profit MarginProfitability
21.9%9/10

Keeps 22 of every $100 in revenue as profit

Price/BookValuation
2.0x8/10

Reasonable price relative to book value

Revenue GrowthGrowth
16.7%8/10

16.7% revenue growth

PRE3 strengths · Avg: 9.3/10
Revenue GrowthGrowth
107.7%10/10

Revenue surging 107.7% year-over-year

Debt/EquityHealth
0.0010/10

Conservative balance sheet, low leverage

Price/BookValuation
2.6x8/10

Reasonable price relative to book value

Areas to Watch

MKC3 concerns · Avg: 3.3/10
PEG RatioValuation
2.234/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.584/10

Distress zone — elevated risk

EPS GrowthGrowth
-14.2%2/10

Earnings declined 14.2%

PRE4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$310.43M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-22.1%2/10

ROE of -22.1% — below average capital efficiency

Free Cash FlowQuality
$-12.33M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : MKC

The strongest argument for MKC centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 21.9% and operating margin at 17.4%. Revenue growth of 16.7% demonstrates continued momentum.

Bull Case : PRE

The strongest argument for PRE centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 107.7% demonstrates continued momentum.

Bear Case : MKC

The primary concerns for MKC are PEG Ratio, Altman Z-Score, EPS Growth.

Bear Case : PRE

The primary concerns for PRE are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

MKC profiles as a growth stock while PRE is a hypergrowth play — different risk/reward profiles.

MKC carries more volatility with a beta of 0.63 — expect wider price swings.

PRE is growing revenue faster at 107.7% — sustainability is the question.

MKC generates stronger free cash flow (337M), providing more financial flexibility.

Bottom Line

MKC scores higher overall (69/100 vs 32/100), backed by strong 21.9% margins and 16.7% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

McCormick & Company Incorporated

CONSUMER DEFENSIVE · PACKAGED FOODS · USA

McCormick & Company is an American multinational food company that manufactures, markets, and distributes spices, seasoning mixes, condiments, and other flavoring products to retail outlets, food manufacturers, and foodservice businesses.

Prenetics Global Ltd

CONSUMER DEFENSIVE · PACKAGED FOODS · USA

Prenetics Global Ltd (PRE) is an innovative health technology company that specializes in advanced genetic and diagnostic testing solutions, offering invaluable health insights to consumers and healthcare professionals alike. With a robust focus on research and development, Prenetics has built a strong international footprint through strategic partnerships and collaborations, enhancing its market visibility. As a frontrunner in personalized medicine, the company is strategically positioned to leverage the growing demand for accessible health data, presenting a compelling investment opportunity within the dynamic healthcare sector.

Want to dig deeper into these stocks?